DBS ON for Hoarseness

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Hoarseness+2 More
DBS ON - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying DBS to see if it can help people with spasmodic dysphonia.

Eligible Conditions
  • Hoarseness
  • Spasmodic Dysphonia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Patient Voice-Related Quality of Life
Patient Voice-Related Quality of Life as assessed by the Voice-Related Quality of Life questionnaire.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

DBS On
1 of 2
DBS Off
1 of 2

Experimental Treatment

Non-Treatment Group

16 Total Participants · 2 Treatment Groups

Primary Treatment: DBS ON · Has Placebo Group · Phase 2

DBS On
Device
Experimental Group · 1 Intervention: DBS ON · Intervention Types: Device
DBS Off
Device
ShamComparator Group · 1 Intervention: DBS OFF · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,315 Previous Clinical Trials
1,267,893 Total Patients Enrolled
1 Trials studying Hoarseness
6 Patients Enrolled for Hoarseness
Christopher R Honey, MDPrincipal InvestigatorUniversity of British Columbia

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The diagnosis of spasmodic dysphonia is evaluated by two centres - one team in Vancouver and the other team in Indiana.
The patient is receiving Botox treatments to help improve their appearance

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: November 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References